Innovent and IASO Bio Present Updated Long-Term Follow-Up Da

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

Hong Kong , Tongji , Sichuan , China , Taiwan , United States , Macau , Huazhong , Hubei , Suzhou , Jiangsu , Chinese , Lugui Qiu , Eli Lilly , Innovent Biologics , Chunrui Li , Equecabtagene Autoleucel , Adimab Incyte , Incyte Corporation , Prnewswire Innovent Biologics Inc , Huazhong University Of Science Technology , Tongji Medical College , International Myeloma Society , China National Medical Products Administration , Md Anderson Cancer Center , Chinese Academy Of Medical Science Hematology Hospital , Complete Response , Abstract Code , Myeloma Society , Annual Meeting , Refractory Multiple , Chinese Academy , Medical Science Hematology Hospital , Tongji Hospital , Huazhong University , Sintilimab Injection , Bevacizumab Injection , Adalimumab Injection , Rituximab Injection , Pemigatinib Oral Inhibitor , Ramucirumab Injection , Selpercatinib Capsules , Equecabtagene Autoleucel Injection , Tafolecimab Injection , Cancer Center , Mainland China , New Drug Application , National Medical Products Administration ,